Inclusion criteria:  Adult, ≥18 years of age Singleton pregnancy, 12 to end of 32 weeks single gestation at randomization In a major depressive episode (MDE) with at least moderate symptom severity (PHQ-9 ≥10 and confirmed using MINI International Neuropsychiatric Interview as MDE without psychotic features) Assessed by a psychiatrist at one of the study recruitment sites during pregnancy, and offered the option of antidepressant medication for treatment but declined to use No new treatments for depression (i.e. psychological or somatic) and no pharmacological treatment for depression in the 4 weeks prior to starting treatment  Exclusion criteria:  Active alcohol or substance use disorder in previous 12 months as assessed by GAIN-SS Active suicidality as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) Bipolar disorder as assessed by MINI International Neuropsychiatric Interview Schizophrenia or other psychotic disorder as assessed by MINI International Neuropsychiatric Interview Major unstable or life-threatening medical illness (e.g. such as advanced cancer), pre-eclampsia/eclampsia in current pregnancy or neurologic illness or seizure history Major congenital anomalies or major obstetrical complications in current pregnancy (determined by clinical PI/Co-I assessment) Metal implants in cranium or any electrical implants Benzodiazepine (except intermittent low-dose lorazepam no more than 2mg equivalent per day) or anticonvulsant use as these interfere with anodal tDCS Visibly non-intact skin/rash on scalp areas at stimulation electrode sites Unable to consent or complete study measures in English, or unable to complete depression in pregnancy workbook (the attention-control) in French or English